Journals / Aksaray Üniversitesi Tıp Bilimleri Dergisi / 2026 / Cilt: 6 Sayı: 3

Artificial Intelligence in Cardiology and Cardiovascular Surgery in Türkiye Current Footprint, Global Benchmarking, and Priority Actions for Scalable Clinical Impact

Türkiye'de Kardiyoloji ve Kardiyovasküler Cerrahide Yapay Zeka. Mevcut Durum, Küresel Karşılaştırma ve Ölçeklenebilir Klinik Etki için Öncelikli Eylemler

Hakan Göçer(Private Umit Hospital, Eskişehir)0000-0002-9644-9579
Pages
127–130
Publication Date
2026-09-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

With a growing scholarly base, supportive journals, and nascent infrastructure, Türkiye is well positioned to emerge as a regional leader in cardiovascular AI, provided that methodological rigor and real-world validation remain central to future work.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Artificial intelligence is rapidly transforming cardiovascular medicine, with global leaders like the USA, China, and UK setting benchmarks in research and implementation.
📊
Key Findings & Data:Priority actions include transitioning from retrospective, single-center studies to multi-center prospective validation, establishing a national AI–CVD data consortium using federated infrastructures and standardized models, implementing clinical MLOps frameworks with auditable governance, aligning publication strategies with clinical relevance, and integrating research efforts with national initiatives through pragmatic trial designs.
💡
Conclusion & Impact:With a growing scholarly base, supportive journals, and nascent infrastructure, Türkiye is well positioned to emerge as a regional leader in cardiovascular AI, provided that methodological rigor and real-world validation remain central to future work.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:kardiyovasküler cerrahi · kardiyoloji · yapay zeka

Abstract

Artificial intelligence is rapidly transforming cardiovascular medicine, with global leaders like the USA, China, and UK setting benchmarks in research and implementation. Recent position papers by the EACVI/EANM and the American Heart Association emphasize the importance of methodological rigor, clinical validation, and equitable adoption before large-scale integration. Türkiye’s contribution is increasing, with high-impact reviews on AI-based clinical decision support, coronary artery disease, atrial fibrillation, and interventional cardiology gaining international citations. These successes highlight Türkiye’s potential for global visibility when aligned with priority topics and robust methodology. The national journal ecosystem offers complementary dissemination pathways. Systemic enablers, such as the Ministry of Health’s Artificial Intelligence Projects Implementation Unit and initiatives linking real-time AI monitoring in ICUs to the e-Nabız platform, are emerging. Priority actions include transitioning from retrospective, single-center studies to multi-center prospective validation, establishing a national AI–CVD data consortium using federated infrastructures and standardized models, implementing clinical MLOps frameworks with auditable governance, aligning publication strategies with clinical relevance, and integrating research efforts with national initiatives through pragmatic trial designs. With a growing scholarly base, supportive journals, and nascent infrastructure, Türkiye is well positioned to emerge as a regional leader in cardiovascular AI, provided that methodological rigor and real-world validation remain central to future work.

Özet

Yapay zeka, ABD, Çin ve İngiltere gibi küresel liderlerin araştırma ve uygulamada kıyas noktaları belirlemesiyle kardiyovasküler tıbbı hızla dönüştürüyor. EACVI/EANM ve Amerikan Kalp Derneği tarafından yayınlanan son pozisyon kağıtları, büyük ölçekli entegrasyondan önce metodolojik titizliğin, klinik doğrulamanın ve adil benimsemenin önemini vurgulamaktadır. Türkiye'nin katkısı artıyor, yapay zeka tabanlı klinik karar destek, koroner arter hastalığı, atriyal fibrilasyon ve girişimsel kardiyoloji üzerine yapılan yüksek etkili incelemeler uluslararası atıf alıyor. Bu başarılar, Türkiye'nin öncelikli konularla ve sağlam bir metodolojiyle uyumlu hale getirildiğinde küresel görünürlük potansiyelini vurgulamaktadır. Ulusal dergi ekosistemi tamamlayıcı yaygınlaştırma yolları sunmaktadır. Sağlık Bakanlığı Yapay Zeka Projeleri Uygulama Birimi ve yoğun bakım ünitelerinde gerçek zamanlı yapay zeka izlemesini e-Nabız platformuna bağlayan girişimler gibi sistemik kolaylaştırıcılar ortaya çıkıyor. Öncelikli eylemler arasında geriye dönük, tek merkezli çalışmalardan çok merkezli, ileriye dönük doğrulamaya geçiş, federatif altyapılar ve standartlaştırılmış modeller kullanarak ulusal bir yapay zeka–KVS veri konsorsiyumu oluşturma, denetlenebilir yönetişime sahip klinik MLOps çerçevelerini uygulama, yayın stratejilerini klinik öneme göre uyarlama ve pragmatik deneme tasarımları aracılığıyla araştırma çabalarını ulusal girişimlerle entegre etme yer almaktadır. Gelişen bilimsel tabanı, destekleyici dergileri ve yeni ortaya çıkan altyapısıyla Türkiye, metodolojik titizlik ve gerçek dünya doğrulaması gelecekteki çalışmaların merkezinde kalmaya devam ettiği sürece, kardiyovasküler yapay zeka alanında bölgesel bir lider olarak ortaya çıkmak için iyi bir konumdadır.

🔖

Cite This Article

Göçer, H., Durukan, A. B. (2026). Artificial Intelligence in Cardiology and Cardiovascular Surgery in Türkiye Current Footprint, Global Benchmarking, and Priority Actions for Scalable Clinical Impact. Aksaray Üniversitesi Tıp Bilimleri Dergisi, Cilt: 6 Sayı: 3, 127–130. https://ajindex.com/articles/1447363

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Türk Karaciğer Araştırmaları Derneği (TKAD), Viral Hepatitle Savaşım Derneği. Türkiye Hepatit B Tanı ve Tedavi Kılavuzu 2023: 6-28.
  2. Türk Karaciğer Araştırmaları Derneği (TKAD), Viral Hepatitle Savaşım Derneği. Türkiye Hepatit C Tanı ve Tedavi Kılavuzu 2023: 5-27.
  3. European Association for the Study of the Liver (EASL). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-98.
  4. European Association for the Study of the Liver (EASL). EASL recommendations on treatment of hepatitis C. J Hepatol. 2020;73:1170-218.
  5. Centers for Disease Control and Prevention (CDC). Considerations for Blood Glucose Monitoring and Insulin Administration (infection control guidance). http://www.cdc.gov/injection-safety/hcp/infection-control/index. (August 7, 2024).
  6. Schaefer MK, Kossover RA, Perz JF. Sharing insulin pens: are you putting patients at risk? Diabetes Care. 2013 Nov;36(11):e188-9.
  7. Advisory Committee on Immunization Practices (ACIP). Use of Hepatitis B Vaccination for Adults With Diabetes Mellitus. MMWR. 2011;60:1709-1711.
  8. Fasil A, Geremew D, Bewket G, et al. Seroprevalence of HBV and HCV Among Diabetes Mellitus Patients Attending University of Gondar Hospital, Northwest Ethiopia. Clin Lab. 2022;68(9).
  9. Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann Intern Med. 2017;166(11):792–798.
  10. Merza MA. Seroprevalence and risk factors of hepatitis B and C viruses among diabetes mellitus patients in Duhok province, Iraqi Kurdistan. J Family Med Prim Care. 2020;9(2):642-6.
  11. Eliah DT, Chamba NG, Sadiq AM, et al. Seroprevalence and associated factors for hepatitis B and hepatitis C viral infection among patients with diabetes mellitus in Northern Tanzania. PLoS One. 2025;20(2):e0319198.
  12. Hong YS, Chang Y, Ryu S, et al. Hepatitis B and C virus infection and diabetes mellitus: A cohort study. Sci Rep. 2017;7(1):4606.
  13. Lapumnuaypol K, Pisarcik D, Putthapiban P, et al. Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: A systematic review & meta-analysis. Indian J Med Res. 2020;152(6):562-7.
  14. Zhou Y, Xie W, Zheng C, et al. Hypoglycemia associated with direct-acting anti-hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS). Clin Endocrinol (Oxf). 2022;96(5):690-7.
  15. Ciancio A, Bosio R, Bo S, et al. Significant improvement of glycemic control in diabetic patients with HCV infection responding to direct-acting antiviral agents. J Med Virol. 2018;90:320–7.